Translating the renoprotective effects of SGLT2 inhibitors to the diabetic retina

Abstract

Keywords

SGLT2 inhibitors diabetic nephropathy diabetic retinopathy

Get full access to this article

View all access options for this article.

References

Chen

Zhang

You

, et al. Investigating the impact of empagliflozin on the retina of diabetic mice. Eur J Ophthalmol 2025; 35: 252–261. doi:https://doi.org/10.1177/11206721241247585

Tesfaye

Paik

Roh

, et al. Empagliflozin and the risk of retinopathy in patients with type 2 diabetes. JAMA Ophthalmol 2025; 143: 62–71. doi:https://doi.org/10.1001/jamaophthalmol.2024.5219

Jacob

Varughese

. Optimising renal risk parameters in type 2 diabetes mellitus: perspectives from a retinal viewpoint. Clin Med (Lond) 2024; 24: 100031. doi:https://doi.org/10.1016/j.clinme.2024.100031

Shaw

Jenkins

. Diabetic retinopathy-another possible target for SGLT2 inhibitors? JAMA Ophthalmol 2025; 143: 71–72. doi:https://doi.org/10.1001/jamaophthalmol.2024.5364

Varughese

Varadhan

. SGLT2 Inhibitors and diabetic retinopathy: insights from the management of nephropathy. Eye (Lond) 2025; 39: 213–214. doi:https://doi.org/10.1038/s41433-024-03472-9